We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

POSTERIOR SUB-TENON'S Avastin

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2008 by Asociación para Evitar la Ceguera en México.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00567372
First Posted: December 4, 2007
Last Update Posted: December 8, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Asociación para Evitar la Ceguera en México
November 30, 2007
December 4, 2007
December 8, 2008
June 2008
November 2008   (Final data collection date for primary outcome measure)
macular volume [ Time Frame: baseline, 3,6 and 12 weeks ]
Best corrected visual acuity [ Time Frame: 3 months ]
Complete list of historical versions of study NCT00567372 on ClinicalTrials.gov Archive Site
  • macular thickness [ Time Frame: baseline,3,6 and 12 weeks ]
  • best corrected visual acuity [ Time Frame: baseline, 3,6 and 12 weeks ]
Not Provided
Not Provided
Not Provided
 
POSTERIOR SUB-TENON'S Avastin
POSTERIOR SUB-TENON'S CAPSULE INJECTION OF BEVACIZUMAB FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA
Posterior sub-tenon's injection of bevacizumab decreased diffuse diabetic macular edema
Not Provided
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Diffuse Diabetic Macular Edema
Drug: bevacizumab (Sub-tenon´s injection)
a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
7
June 2009
November 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Patients with diffuse diabetic macular edema non-proliferative diabetic retinopathy Maculat thickness ≥250 μ BCVA ≥ 20/400 Without any treatment

Sexes Eligible for Study: All
25 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Mexico
 
 
NCT00567372
00922
No
Not Provided
Not Provided
Sandra Vera-Rodriguez, Asociación para Evitar la Ceguera en Mexico IAP
Asociación para Evitar la Ceguera en México
Not Provided
Principal Investigator: Sandra Vera, MD Asociación para Evitar la Ceguera en Mexico
Principal Investigator: Hugo Quiroz-Mercado, MD Denver Health Medical Center
Principal Investigator: Adai Pérez-Montesinos, MD Asociación para Evitar la Ceguera en Mexico
Asociación para Evitar la Ceguera en México
December 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP